Moderna Inc (MRNA)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 43% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+662% over the past year+10
- 52-week positionAbove the midpoint of its 52-week range+9
- QualityRevenue shrinking (-28% y/y)-11
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is product (the late-stage mRNA bird flu vaccine trial), with index inclusion and momentum headlines acting as secondary supports rather than the core driver. Continuation over the next few weeks is a moderate-probability scenario (roughly 40–50%), since trial news tends to fade without follow-through data while index-inclusion flows are largely one-time. Informational only — not financial advice.
- FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B StudyBenzinga · 2026-10-22
- Moderna (MRNA) Starts Late Stage Trial For mRNA Bird Flu VaccineYahoo · 2026-10-22
- Is Moderna (MRNA) Fully Valued Following Its NASDAQ 100 Inclusion?Yahoo · 2026-10-22
- Why Did MRNA, CVX, V Stocks Jump To 52-Week Highs Today?Yahoo · 2026-10-22
- Moderna (MRNA) Rises Higher Than Market: Key FactsYahoo · 2026-10-21
Any AI summary is an interpretation of public news, not advice or a price target.